Pharmaceutical composition for nasal delivery
US12268684B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 18, 2023 |
| Grant date | Apr 8, 2025 |
| Priority date | — |
| Expiry date | Dec 18, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/1682
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.